Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study.

Lapointe-Shaw L, Georgie F, Carlone D, Cerocchi O, Chung H, Dewit Y, Feld JJ, Holder L, Kwong JC, Sander B, Flemming JA.

PLoS One. 2018 Aug 22;13(8):e0201120. doi: 10.1371/journal.pone.0201120. eCollection 2018.

2.

The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis.

Jhaveri KS, Hosseini-Nik H, Sadoughi N, Janssen H, Feld JJ, Fischer S, Menezes R, Cheung AC.

Eur Radiol. 2018 Jul 26. doi: 10.1007/s00330-018-5619-4. [Epub ahead of print]

PMID:
30051141
3.

IL-15 and IFN-γ signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling.

Vahedi F, Lee AJ, Collins SE, Chew MV, Lusty E, Chen B, Dubey A, Richards CD, Feld JJ, Russell RS, Mossman KL, Ashkar AA.

Cytokine. 2018 Jun 13. pii: S1043-4666(18)30254-0. doi: 10.1016/j.cyto.2018.06.006. [Epub ahead of print]

PMID:
29908921
4.

Tenofovir to Prevent Perinatal Transmission of Hepatitis B.

Terrault NA, Feld JJ, Lok ASF.

N Engl J Med. 2018 Jun 14;378(24):2348-9. doi: 10.1056/NEJMc1805396. No abstract available.

PMID:
29900725
5.

The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.

Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver.

CMAJ. 2018 Jun 4;190(22):E677-E687. doi: 10.1503/cmaj.170453. No abstract available.

6.

Approaches for simplified HCV diagnostic algorithms.

Fourati S, Feld JJ, Chevaliez S, Luhmann N.

J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25058. doi: 10.1002/jia2.25058. Review.

7.

Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B.

Khalili M, Shuhart MC, Lombardero M, Feld JJ, Kleiner DE, Chung RT, Terrault NA, Lisker-Melman M, Sanyal A, Lok AS; Hepatitis B Research Network (HBRN); Harvard Consortium.

Diabetes Care. 2018 Jun;41(6):1251-1259. doi: 10.2337/dc18-0040. Epub 2018 Mar 29.

PMID:
29599296
8.

Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.

Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N, Stamm LM, Hyland RH, McNally J, Brainard DM, Jacobson I, Zeuzem S, Bourlière M, Foster G, Afdhal N, Dore GJ.

Open Forum Infect Dis. 2018 Feb 9;5(2):ofy001. doi: 10.1093/ofid/ofy001. eCollection 2018 Feb.

9.

Hepatitis B Reactivation With Hepatitis C Treatment: Bringing Some Clarity to the Black Box.

Ma AT, Feld JJ.

Gastroenterology. 2018 Mar;154(4):795-798. doi: 10.1053/j.gastro.2018.02.005. Epub 2018 Feb 6. No abstract available.

PMID:
29425929
10.

Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review.

Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe AYM, Miller V, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL.

Hepatol Commun. 2017 May 22;1(5):379-390. doi: 10.1002/hep4.1050. eCollection 2017 Jul. Review.

11.

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.

Feld JJ, Bernstein DE, Younes Z, Vlierberghe HV, Larsen L, Tatsch F, Ferenci P.

Liver Int. 2018 Sep;38(9):1571-1575. doi: 10.1111/liv.13708. Epub 2018 Mar 14.

PMID:
29377566
12.

Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.

Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ.

N Engl J Med. 2018 Jan 25;378(4):354-369. doi: 10.1056/NEJMoa1702417.

13.

Population-based estimate of hepatitis C virus prevalence in Ontario, Canada.

Bolotin S, Feld JJ, Garber G, Wong WWL, Guerra FM, Mazzulli T.

PLoS One. 2018 Jan 23;13(1):e0191184. doi: 10.1371/journal.pone.0191184. eCollection 2018.

14.

Extending a Helping Hand: Addressing Hepatitis C in Economic Migrants and Refugees.

Feld JJ.

Ann Hepatol. 2018 January-February;17(1):8-10. doi: 10.5604/01.3001.0010.7529. No abstract available.

15.

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.

Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group.

Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6.

PMID:
29310928
16.

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.

Sulkowski MS, Feld JJ, Lawitz E, Felizarta F, Corregidor AM, Khalid O, Ghalib R, Smith WB, Van Eygen V, Luo D, Vijgen L, Gamil M, Kakuda TN, Ouwerkerk-Mahadevan S, Van Remoortere P, Beumont M.

J Viral Hepat. 2018 Jun;25(6):631-639. doi: 10.1111/jvh.12853. Epub 2018 Feb 6.

PMID:
29274193
17.

Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: A systematic review and meta-analysis.

Erman A, Sathya A, Nam A, Bielecki JM, Feld JJ, Thein HH, Wong WWL, Grootendorst P, Krahn MD.

J Viral Hepat. 2018 May;25(5):502-513. doi: 10.1111/jvh.12846. Epub 2018 Jan 24.

PMID:
29239068
18.

Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.

Bhardwaj N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, Martin R, Chang S, Miller MD, Feld JJ, Sulkowski M, Mangia A, Wertheim JO, Osinusi A, McNally J, Brainard D, Mo H, Svarovskaia ES.

J Viral Hepat. 2018 Apr;25(4):344-353. doi: 10.1111/jvh.12825. Epub 2017 Dec 28.

PMID:
29112331
19.

Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis.

Grebely J, Applegate TL, Cunningham P, Feld JJ.

Expert Rev Mol Diagn. 2017 Dec;17(12):1109-1115. doi: 10.1080/14737159.2017.1400385. Epub 2017 Nov 8. Review.

PMID:
29088981
20.

Risk for Hepatocellular Carcinoma After Hepatitis C Virus Antiviral Therapy With Direct-Acting Antivirals: Case Closed?

Maan R, Feld JJ.

Gastroenterology. 2017 Oct;153(4):890-892. doi: 10.1053/j.gastro.2017.08.052. Epub 2017 Sep 1. No abstract available.

PMID:
28867275
21.

Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment.

Feld JJ, Pawlotsky JM, Tatsch F, Sulkowski M, Poordad F, Jacobson I.

Liver Int. 2017 Nov;37(11):1743-1744. doi: 10.1111/liv.13567. No abstract available.

PMID:
28853201
22.

Model-based projection of health and economic effects of screening for hepatitis C in Canada.

Wong WWL, Erman A, Feld JJ, Krahn M.

CMAJ Open. 2017 Aug 25;5(3):E662-E672. doi: 10.9778/cmajo.20170048.

23.

Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.

Sharma SA, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, Janssen HLA, Sherman M, Hirschfield GM, Feld JJ.

J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248-1. doi: 10.1016/j.jhep.2017.07.033. [Epub ahead of print]

PMID:
28844936
24.

Treatment of hepatitis B virus with combination therapy now and in the future.

Emery JS, Feld JJ.

Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):347-355. doi: 10.1016/j.bpg.2017.04.007. Epub 2017 May 4. Review.

PMID:
28774417
25.

Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.

Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Gane EJ, Feld JJ, Mangia A.

Liver Int. 2018 Mar;38(3):443-450. doi: 10.1111/liv.13534. Epub 2017 Oct 22.

PMID:
28756625
26.

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L, Midgard H, Larney S, Degenhardt L, Alho H, Byrne J, Dillon JF, Feld JJ, Foster G, Goldberg D, Lloyd AR, Reimer J, Robaeys G, Torrens M, Wright N, Maremmani I, Norton BL, Litwin AH, Dore GJ; International Network on Hepatitis in Substance Users.

Int J Drug Policy. 2017 Sep;47:51-60. doi: 10.1016/j.drugpo.2017.05.019. Epub 2017 Jul 3.

27.

Editorial: hepatitis C direct acting antiviral agents and the kidney-authors' reply.

Maan R, Feld JJ, Duarte-Rojo A.

Aliment Pharmacol Ther. 2017 Aug;46(3):379-380. doi: 10.1111/apt.14187. No abstract available.

PMID:
28677289
28.

Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.

Poordad F, Nelson DR, Feld JJ, Fried MW, Wedemeyer H, Larsen L, Cohen DE, Cohen E, Mobashery N, Tatsch F, Foster GR.

J Hepatol. 2017 Oct;67(4):700-707. doi: 10.1016/j.jhep.2017.06.011. Epub 2017 Jun 21. Review.

29.

Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation.

Chi H, Wong D, Peng J, Cao J, Van Hees S, Vanwolleghem T, Qi X, Chen L, Feld JJ, de Knegt RJ, Hansen BE, Janssen HLA.

Clin Infect Dis. 2017 Aug 15;65(4):680-683. doi: 10.1093/cid/cix353.

PMID:
28575292
30.

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.

Feld JJ, Ramji A, Shafran SD, Willems B, Marotta P, Huchet E, Vachon ML, Svarovskaia ES, Huang KC, Hyland RH, Yun C, Massetto B, Brainard DM, McHutchison JG, Tam E, Bailey R, Cooper C, Yoshida EM, Greenbloom S, Elkhashab M, Borgia S, Swain MG.

Clin Infect Dis. 2017 Jul 1;65(1):13-19. doi: 10.1093/cid/cix289.

PMID:
28535298
31.

The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.

Maan R, Al Marzooqi SH, Klair JS, Karkada J, Cerocchi O, Kowgier M, Harrell SM, Rhodes KD, Janssen HLA, Feld JJ, Duarte-Rojo A.

Aliment Pharmacol Ther. 2017 Jul;46(1):46-55. doi: 10.1111/apt.14117. Epub 2017 May 3.

PMID:
28470850
32.

Hepatitis B Reactivation: The Controversies Continue.

Feld JJ.

Dig Dis. 2017;35(4):351-358. doi: 10.1159/000456587. Epub 2017 May 3. Review.

PMID:
28468014
33.

Replication and Oncolytic Activity of an Avian Orthoreovirus in Human Hepatocellular Carcinoma Cells.

Kozak RA, Hattin L, Biondi MJ, Corredor JC, Walsh S, Xue-Zhong M, Manuel J, McGilvray ID, Morgenstern J, Lusty E, Cherepanov V, McBey BA, Leishman D, Feld JJ, Bridle B, Nagy É.

Viruses. 2017 Apr 24;9(4). pii: E90. doi: 10.3390/v9040090.

34.

Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.

Welzel TM, Asselah T, Dumas EO, Zeuzem S, Shaw D, Hazzan R, Forns X, Pilot-Matias T, Lu W, Cohen DE, Feld JJ.

Lancet Gastroenterol Hepatol. 2017 Jul;2(7):494-500. doi: 10.1016/S2468-1253(17)30071-7. Epub 2017 Apr 14.

PMID:
28416221
35.

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.

Asselah T, Hézode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, Feld JJ, Moreno C, Zeuzem S, Ferenci P, Yu Y, Redman R, Pilot-Matias T, Mobashery N.

Lancet Gastroenterol Hepatol. 2016 Sep;1(1):25-35. doi: 10.1016/S2468-1253(16)30001-2. Epub 2016 Jun 16.

PMID:
28404108
36.

Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.

Wong WW, Lee KM, Singh S, Wells G, Feld JJ, Krahn M.

CMAJ Open. 2017 Feb 3;5(1):E97-E108. doi: 10.9778/cmajo.20160161. eCollection 2017 Jan-Mar.

37.

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Bräu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR.

Gastroenterology. 2017 Jul;153(1):113-122. doi: 10.1053/j.gastro.2017.03.047. Epub 2017 Apr 5.

PMID:
28390869
38.

Overcoming the resistance to resistance testing: Collecting the data.

Doyle A, Feld JJ.

Liver Int. 2017 Apr;37(4):506-508. doi: 10.1111/liv.13360. No abstract available.

PMID:
28371101
39.

HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.

Rockstroh JK, Feld JJ, Chevaliez S, Cheng K, Wedemeyer H, Sarrazin C, Maasoumy B, Herman C, Hackett J Jr, Cohen DE, Dawson GJ, Cloherty G, Pawlotsky JM.

J Virol Methods. 2017 Jul;245:14-18. doi: 10.1016/j.jviromet.2017.03.002. Epub 2017 Mar 27.

40.

Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.

Emery JS, Kuczynski M, La D, Almarzooqi S, Kowgier M, Shah H, Wong D, Janssen HLA, Feld JJ.

Am J Gastroenterol. 2017 Aug;112(8):1298-1308. doi: 10.1038/ajg.2017.49. Epub 2017 Mar 14.

PMID:
28291241
41.

Corrigendum to "Second generation direct-acting antivirals - do we expect major improvements?"

Feld JJ, Foster GR.

J Hepatol. 2017 May;66(5):1105. doi: 10.1016/j.jhep.2017.02.015. Epub 2017 Mar 7. No abstract available.

PMID:
28283248
42.

Race or genetic makeup for hepatitis C virus treatment decisions?

O'Brien TR, Kottilil S, Feld JJ, Morgan TR, Pfeiffer RM.

Hepatology. 2017 Jun;65(6):2124-2125. doi: 10.1002/hep.29057. Epub 2017 Apr 18. No abstract available.

43.

Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.

Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Krajden M, Shoukry NH, Taylor LE, Grebely J; Canadian Network on Hepatitis C (CanHepC).

CMAJ Open. 2016 Oct 14;4(4):E605-E614. doi: 10.9778/cmajo.20160008. eCollection 2016 Oct-Dec.

44.

Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.

Alqahtani S, Ozaras R, Isakov V, Wyles D, Ferenci P, Feld JJ, Calinas F, Gschwantler M, Gane E, Crawford D, Jacobson IM, Dumas EO, King M, Sulkowski M.

J Viral Hepat. 2017 Apr;24(4):280-286. doi: 10.1111/jvh.12641. Epub 2016 Dec 9.

PMID:
27935166
45.

Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation-A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion.

Goldaracena N, Spetzler VN, Echeverri J, Kaths JM, Cherepanov V, Persson R, Hodges MR, Janssen HL, Selzner N, Grant DR, Feld JJ, Selzner M.

Am J Transplant. 2017 Apr;17(4):970-978. doi: 10.1111/ajt.14100. Epub 2016 Dec 23.

46.

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.

van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D'Ambrosio R, Pol S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HLA.

J Hepatol. 2017 Mar;66(3):485-493. doi: 10.1016/j.jhep.2016.10.017. Epub 2016 Oct 22.

PMID:
27780714
47.

Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response.

Cloherty G, Chevaliez S, Sarrazin C, Herman C, Holzmayer V, Dawson G, Maasoumy B, Vermehren J, Wedemeyer H, Feld JJ, Pawlotsky JM.

Sci Rep. 2016 Oct 20;6:35410. doi: 10.1038/srep35410.

48.

Second generation direct-acting antivirals - Do we expect major improvements?

Feld JJ, Foster GR.

J Hepatol. 2016 Oct;65(1 Suppl):S130-S142. doi: 10.1016/j.jhep.2016.07.007. Review.

PMID:
27641983
49.

Absolute Ligand Discrimination by Dimeric Signaling Receptors.

Fathi S, Nayak CR, Feld JJ, Zilman AG.

Biophys J. 2016 Sep 6;111(5):917-20. doi: 10.1016/j.bpj.2016.07.029.

50.

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.

Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Natha M, Foster GR, Mangia A, Sulkowski M, Feld JJ.

Clin Infect Dis. 2016 Dec 1;63(11):1479-1481. Epub 2016 Aug 23.

Supplemental Content

Support Center